Compare Quest Diagnostics Inc (DGX) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Meta Platforms Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Meta Platforms Inc trades at $663.25 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 73.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | META | |
|---|---|---|
Market Cap | $22.80B | $1.68T |
Sector | Health | Media |
52-Week High | $216.02 | $790.00 |
52-Week Low | $166.42 | $525.72 |
Enterprise Value | $28.82B | $1.68T |
Dividend Yield | 1.67% | 0.32% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Meta Platforms (META) trades at $656.73, down 1.86% on the day, but maintains strong technical momentum with a bullish moving average signal and key resistance at $663. Fundamentally, the company demonstrates robust profitability with 32.84% net income margin and consistent earnings beats, including Q1 2026 EPS of $10.44 versus $6.70 expected. Recent AI developments, including the Muse Spark launch on April 10, 2026, highlight growth initiatives.
The outlook remains positive with 79% analyst buy ratings and a $815.44 consensus price target suggesting 24% upside. Key risks include ongoing litigation, particularly the Massachusetts youth addiction lawsuit ruled on April 10, 2026, and elevated capital expenditures. Revenue growth trajectory and AI monetization present significant opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
